ICER Outlines Planned Review of Hemophilia A Treatments
January 24, 2020
The Institute for Clinical and Economic Review (ICER) released a draft scoping document outlining its planned review of two treatments for hemophilia A: BioMarin Pharmaceutical’s valoctocogene roxaparvovec and Genentech’s Hemlibra.
The document is open to public feedback until 5 p.m. EST Feb. 13.
To read the document, click here.